EUVIMEDEUVIMED entdecken
Crossref

Propranolol: A novel therapy for neonatal chylothorax secondary to congenital lymphatic anomaly

Aashish Gupta, Mary Woodward, Emer Finan, Bonny Jasani

Journal of Clinical Insights in Neonatology · 2025

DOI: 10.3138/jcin-2025-0008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Insights in Neonatology, 2025. Verfasst von Aashish Gupta und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neonatal chylothorax, a common cause of pleural effusion in neonates, can occur secondary to trauma or from primary congenital causes. Congenital chylothorax due to chromosomal anomalies or lymphatic malformations can result in refractory chylothorax. Medical management using octreotide, sildenafil, and sirolimus has shown variable success, particularly with congenital chylothorax. These pharmacotherapeutic options have different adverse effect profiles that must be balanced against their effectiveness. Case Presentation: A late preterm infant was born to a consanguineous couple with antenatal suspicion of bilateral pleural effusion. After birth, the infant experienced respiratory distress, and bilateral chest tubes were placed, which drained significant amounts of chylous effusion over the subsequent 4 weeks. Whole genome sequencing revealed a PIEZO-1 mutation associated with congenital lymphatic anomaly. Conventional medical management, including intercostal drainage, medium-chain triglyceride-enriched formula, parenteral nutrition, prednisolone, and octreotide, was continued for an 8-week period without resolution. Propranolol was then initiated, leading to complete resolution of chylothorax. The infant was discharged home on propranolol with no recurrence noted on follow-up.

Conclusion

This case report indicates that propranolol can be used as an effective therapy to treat moderate to severe chylothorax, especially in the context of congenital lymphatic anomaly, mainly because of its anti-vascular endothelial growth factor action.

Zitieren

APA

Gupta, A., Woodward, M., Finan, E., & Jasani, B. (2025). Propranolol: A novel therapy for neonatal chylothorax secondary to congenital lymphatic anomaly. Journal of Clinical Insights in Neonatology. https://doi.org/10.3138/jcin-2025-0008

Vancouver

Gupta A, Woodward M, Finan E, Jasani B. Propranolol: A novel therapy for neonatal chylothorax secondary to congenital lymphatic anomaly. Journal of Clinical Insights in Neonatology. 2025. doi:10.3138/jcin-2025-0008

BibTeX
@article{Gupta2025,
  author = {Gupta, Aashish and Woodward, Mary and Finan, Emer and Jasani, Bonny},
  title = {Propranolol: A novel therapy for neonatal chylothorax secondary to congenital lymphatic anomaly},
  journal = {Journal of Clinical Insights in Neonatology},
  year = {2025},
  doi = {10.3138/jcin-2025-0008}
}
Kostenlos starten →